Deutsche Bank AG Sells 58,766 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Deutsche Bank AG reduced its stake in Supernus Pharmaceuticals by 55.7%, selling 58,766 shares and now owning only 46,817 shares valued at approximately $1.53 million.
• Multiple other investors, including LPL Financial and Wells Fargo, have increased their holdings in Supernus Pharmaceuticals during the 4th quarter, with LPL Financial raising its stake by 18.9%.
• Analysts have recently upgraded Supernus Pharmaceuticals from a "strong sell" to a "hold" rating, with a consensus target price rising to $41.00 and two analysts rating it as a "buy".

Deutsche Bank AG lowered its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 55.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,817 shares of the specialty pharmaceutical company's stock after selling 58,766 shares during the period. Deutsche Bank AG owned approximately 0.08% of Supernus Pharmaceuticals worth $1,533,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Supernus Pharmaceuticals by 3.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock valued at $1,033,000 after purchasing an additional 1,083 shares during the period. Two Sigma Advisers LP raised its position in shares of Supernus Pharmaceuticals by 14.7% in the 4th quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock worth $282,000 after acquiring an additional 1,000 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of Supernus Pharmaceuticals by 3.2% in the 1st quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock valued at $10,032,000 after purchasing an additional 9,590 shares during the period. Envestnet Asset Management Inc. boosted its position in shares of Supernus Pharmaceuticals by 6.2% during the fourth quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock valued at $2,169,000 after purchasing an additional 3,495 shares in the last quarter. Finally, SG Americas Securities LLC grew its stake in Supernus Pharmaceuticals by 63.6% in the first quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock worth $579,000 after purchasing an additional 6,867 shares during the period.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Cantor Fitzgerald raised their price objective on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, Supernus Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $41.00.

Insider Transactions at Supernus Pharmaceuticals

In related news, CFO Timothy C. Dec sold 11,780 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $44.49, for a total value of $524,092.20. Following the transaction, the chief financial officer directly owned 1,246 shares of the company's stock, valued at approximately $55,434.54. This represents a 90.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Frank Mottola sold 14,000 shares of the company's stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $44.51, for a total value of $623,140.00. Following the completion of the transaction, the senior vice president directly owned 15,496 shares in the company, valued at $689,726.96. This trade represents a 47.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 179,606 shares of company stock worth $7,617,005. Company insiders own 8.80% of the company's stock.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN traded up $0.30 during mid-day trading on Thursday, reaching $45.37. The company had a trading volume of 468,822 shares, compared to its average volume of 1,072,627. The firm has a 50-day moving average price of $36.37 and a 200 day moving average price of $33.90. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $45.60. The company has a market capitalization of $2.54 billion, a price-to-earnings ratio of 39.45 and a beta of 0.74.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.